

# What is the Cervix Cancer Research Network?

January 28, 2015

David Gaffney

Steering Committee: Henry Kitchener, Sang Young Ryu, Bill Small, Carien Creutzberg, D. Thinh, Anuja Jhingran, Linda Mileskin, A.Covens (IGCS) and Monica Bacon

# Why do we need the Cervix Cancer Research Network (CCRN)

- Too many women die from cervix cancer
- Too many women suffer from cervix cancer
- Research is difficult, but possible in cervix cancer

Cervix cancer is a leading cause of death in women from Low “Development Index” countries, but not in high and medium “Development Index” countries.

# CCRN: Goals of this Meeting

- Improve care and clinical research in cervix cancer
- Advance knowledge in cervix brachytherapy
- Support the on-going CCRN trials
- Develop new CCRN trials

# Survey Results: CCRN Participants

	Mean number	Range
# cervix cases/yr	255	6-1000
# rad oncs	5.3	2-15
# physicists	6.5	2-16
# dosimetrists	2.8	0-8
nurses	6.9	1-30
nurses' aides	3.4	0-10
% of patients getting chemoRT	85	60-100
% completing $\leq$ 8 weeks	84	60-100


Response rate of survey: 69%, 22/32.

# Survey Results: CCRN Participants

	Yes (%)	No (%)	Other (%)
Labs available	100	0	
EQD2 conversion sheet used	64	27	9
2nd check of plan by physicist	59	36	5
Ultrasound used for tandem placement	32	41	27
Is uterus sounded	82	14	4
Smit sleeve used	5	86	9
Contrast placed in foley balloon	73	27	
Imaging and planning performed for each fraction	91	9	


# Survey Results

## Prescription




- Point A
- Volume
- Combination
- per case

## Applicator



- T and O
- T and Cylinder
- Combination
- Interstitial

## OAR Reporting



- Point
- Volume
- Both required

# **Cervix Cancer Research Network (CCRN)**

- Managed by the Gynecologic Cancer InterGroup
- Aim is to promote high quality clinical research
- Literature search was performed to evaluate best practices
- Data input required (form developed by the Radiologic Physics Center, Houston, Tx)
- Participation in a beam measurement program (TLD/OSLD) is required every 2 yrs
- Site visits performed by an audit team from GCIG
- QA performed according to trial






FIGURE 1 | Workflow for CCRN site approval.





# CCRN Trials



- TACO (KGOG/Thai)
- OUTBACK (ANZGOG)
- INTERLACE (NCRI)
- SHAPE (NCIC CTG)

> 60 accruals as of August 2015

# CCRN Sites

Site	Trial	Auditors	Outcome
Tata India	OUTBACK	Narayan/Martyn	Approved Not activated
Bangalore India	OUTBACK	Narayan/Martyn	Approved Not activated
Lucknow India	OUTBACK	Narayan/Martyn	Not approved Action pending
<b>Ramathibodi Thailand</b>	<b>TACO</b>	<b>Gaffney/Martyn</b>	<b>Approved Activated</b>
Cluj Romania	INTERLACE	McCormick/Bacon	Pending (infrastructure)
Minsk Belarus	INTERLACE	McCormick/Bacon	Pending (infrastructure)
Trivandrum India	OUTBACK	Jhingran	Approved Not activated
Lahore Pakistan	OUTBACK	Narayan/Mirza	Pending
<b>Siriraj Thailand</b>	<b>TACO</b>	<b>Small/Bacon/ Stonebraker</b>	<b>Approved*</b>
<b>Pramongkutklao Thailand</b>	<b>TACO</b>	<b>Stonebraker/ D.Kim</b>	<b>Approved</b>
<b>Ho Chi Ming Vietnam</b>	<b>TACO</b>	<b>Bacon/Stonebraker</b>	<b>Approved Activated</b>

# CCRN Sites

Location	Trial
Hertzen, Moscow	TACO/SHAPE
<b>Russian Scientific Center of Roentgenoradiology, Moscow</b>	<b>TACO</b>
<b>Blokhin, Moscow</b>	<b>TACO</b>
Zambia, Africa	Not approved -- in progress
Shanghai, China	TACO
<b>Possible Future Sites</b>	
Capetown, S. Africa	
South America (Colombia, Brazil, Argentina)	
Accra, Ghana	
Prague, Czech Republic	
Puerto Rico	

# CCRN: Significant Issues

- Money (Funding Sources)
  - IGCS (current support)
  - GCIG (current support)
  - Center for Global Health, NIH, USA
  - Gates Foundation
  - Industry (Elekta/Varian/Bebig)
    - Burgeoning market
- Per case reimbursement?
- Accrual
- Ongoing oversight (QA and FU)
- Insurance/Indemnity issues
- Site Selection
- Infrastructure (clinical trials management)

# CCRN: Summary

- 4 publically funded Cervix Cancer trials
- > 60 Accruals to date
- Site Selection is challenging
- Many willing expert volunteers
- Participation in cervix trials may improve care for regions and countries
- Very grateful for support from GCIIG, IGCS, and Industry (Elekta, Varian, and Bebig)